At a Glance
- Company: FDA (regulatory action)
- Location: Washington, DC
- Headline figures: 30+ warning letters; targets APIs in non-FDA drugs
- Focus area: Compounded semaglutide/tirzepatide for weight loss
- Next steps: Ingredient restrictions; DOJ referrals
What happened?
The FDA announced plans to restrict active pharmaceutical ingredients used in non-FDA-approved compounded GLP-1 drugs marketed as alternatives to approved products like Ozempic and Wegovy. Recent actions include warning letters to 30 telehealth firms for misleading claims of equivalence, with enforcement against mass-produced copies now supply is stable.
Why does it matter?
Compounded GLP-1s filled access gaps during shortages but quality/safety concerns persist: dosing errors, overdoses and unverified APIs from foreign sources. FDA clarifies compounding only for patient-specific needs, not copies, protecting patients while shrinking a $1B+ grey market as Novo/Lilly ramp production.
Who’s behind it?
FDA Commissioner Marty Makary leads enforcement; Novo Nordisk/Eli Lilly support crackdown. Targets include Hims & Hers for $49 compounded versions; compounders can’t claim identical efficacy/ingredients.
How was it achieved?
Federal law (503A/503B) limits compounding when approved drugs available; FDA greenlists safe imports but flags risky APIs like retatrutide. Warnings cite unproven safety, mass production violations; potential injunctions/seizures follow.
What’s next?
API restrictions implementation; state boards align (e.g., Ohio bans copies). Compounders pivot to true customisation; telehealth faces DOJ scrutiny.